Advertisement

Cardiovascular Disease and Inflammation

  • P. Stenvinkel
  • E. Ritz

Patients with chronic kidney disease (CKD) have a markedly reduced lifespan. Cardiovascular disease (CVD), including stroke, acute myocardial infarction (AMI), sudden death, peripheral vascular disease (PVD), and congestive heart failure (CHF), accounts for premature death in more than 50% of dialysis patients from North America and Europe [1]. As premature CVD accounts for the majority of all-cause mortality, CKD should, like diabetes mellitus (DM), be considered a “high risk” group for CVD [2] and vascular disease should be treated with the same maximum armatorium of drugs and with active interventions, such as coronary artery by-pass graft (CABG), as would be indicated in the high-risk segments of the nonrenal population. This includes the use of antiplatelet agents, angiotensin-converting-enzyme-inhibitors (ACE-I), angiotensin receptor blockers (ARBs), β-blockers, nitroglycerine, and statins.

Keywords

Chronic Kidney Disease Peritoneal Dialysis Dialysis Patient Brain Natriuretic Peptide Chronic Kidney Disease Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal failure. Am J Kidney Dis 1998; 32 (suppl. 5): S112–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003; 42 (5): 1050–1065.PubMedCrossRefGoogle Scholar
  3. 3.
    Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lamiere N. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005; 20: 1048–1056.PubMedCrossRefGoogle Scholar
  4. 4.
    Hallan SI, Josef Coresh C, Astor BC, Åsberg A, Powe NR, Romundstad S, et al. International comparison of the relationship of chronic kidney disease prevalence and ESRD Risk. J Am Soc Nephrol 2006; 17: 2275–2284.PubMedCrossRefGoogle Scholar
  5. 5.
    Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347 (25): 2010–2019.PubMedCrossRefGoogle Scholar
  6. 6.
    Paniagua R, Amato D, Vonesh E, Correa-Rotter R, Ramos A, Moran J, et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 2002;13 (5): 1307–1320.PubMedGoogle Scholar
  7. 7.
    Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998; 9 (12 suppl.): S16–S23.PubMedGoogle Scholar
  8. 8.
    Stenvinkel P, Heimburger O, Lindholm B, Kaysen GA, Bergstrom J. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial Transplant 2000; 15 (7): 953–960.PubMedCrossRefGoogle Scholar
  9. 9.
    Vonesh EF, Snyder JJ, Foley RN, Collins AJ. Mortality studies comapring peritoneal dialysis and haemodialysis: what do they tell us? Kidney Int 2006; 70: S3–S11.CrossRefGoogle Scholar
  10. 10.
    Yoshino M, Kuhlmann MK, Kotanko P, Greenwood RN, Pisoni RL, Port FK, et al. International differences in dialysis mortality reflect background general population atherosclerotic cardiovascular mortality. J Am Soc Nephrol 2006; 17: 3510–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003; 63: 793–808.PubMedCrossRefGoogle Scholar
  12. 12.
    Cheung AK, Sarnak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV, et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 2000; 58 (1): 353–362.PubMedCrossRefGoogle Scholar
  13. 13.
    Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990;15 (5): 458–482.PubMedGoogle Scholar
  14. 14.
    Liu Y, Coresh J, Eustace JA, Longnecker JC, Jaar B, Fink NE, et al. Association between cholesterol level and mortality in dialysis patients. Role of inflammation and malnutrition. JAMA 2004; 291: 451–459.PubMedCrossRefGoogle Scholar
  15. 15.
    Herzog CA, Ma JZ, Collins AJ. Comparative survival of dialysis patients in the United States after coronary angioplasty, coronary artery stenting, and coronary artery bypass surgery and impact of diabetes. Circulation 2002; 106 (17): 2207–2211.PubMedCrossRefGoogle Scholar
  16. 16.
    Orth SR, Ritz E. The renal risks of smoking: an update. Curr Opin Nephrol Hypertens 2002; 11 (5): 483–488.PubMedCrossRefGoogle Scholar
  17. 17.
    Foley RN, Culleton BF, Parfrey PS, Harnett JD, Kent GM, Murray DC, et al. Cardiac disease in diabetic end-stage renal disease. Diabetologia 1997; 40: 1307–1312.PubMedCrossRefGoogle Scholar
  18. 18.
    Morioka T, Emoto M, Tabata T, Shoji T, Tahara H, Kishimoto H, et al. Glycemic control is a predictor of survival for diabetic patients on hemodialysis. Diabetes Care 2001; 24: 903–913.CrossRefGoogle Scholar
  19. 19.
    ACE/AOA rash force on inpatient diabetes. American college of Endocrinology and American Diabetes Association consensus statement on inpatient diabetes and glycemic control. Endocrine pract 2006; 12(13): 4–13.PubMedCrossRefGoogle Scholar
  20. 20.
    Koch M, Thomas B, Tschope W, Ritz E. Survival and predictors of death in dialysed diabetic patients. Diabetologia 1993; 36: 1113–1117.PubMedCrossRefGoogle Scholar
  21. 21.
    Chorra B, Laurent G. Importance of treatment time and blood pressure control in achieving long-term survival on dialysis. Am J Nephrol 1996; 16: 35–44PubMedCrossRefGoogle Scholar
  22. 22.
    Isbel NM, Haluska B, Johnson DW, Beller E, Hawley C, Marwick TH. Increased targeting of cardiovascular risk factors in patients with chronic kidney disease does not improve atheroma burden or cardiovascular function. Am Heart J 2006; 151: 745–753.PubMedCrossRefGoogle Scholar
  23. 23.
    Wang AY-M, Lam W-K., Yu C-M, Wang M, Chan IH-S, Lui S-F, et al. Troponin T, left ventricular mass, and function are excellent predictors of cardiovascular congestion in peritoneal dialysis. Kidney Int 2006; 70: 444–452.PubMedGoogle Scholar
  24. 24.
    Wang AY-M, Lam CW-K, Yu CC-M, Wang M, Chan IH-S, Zhang Y, et al. N-terminal pro-brain natriuretic peptide: An independent risk predictor of cardiovascular congestion, mortality and adverse cardiovascular outcomes in chronic peritoneal dialysis patients. J Am Soc Nephrol 2007; 18: 321–330.PubMedCrossRefGoogle Scholar
  25. 25.
    Harjai KJ. Potential new cardiovascular risk factors: left ventricular hypertrophy, homocysteine, lipoprotein(a), triglycerides, oxidative stress, and fibrinogen. Ann Intern Med 1999; 131 (5): 376–386.PubMedGoogle Scholar
  26. 26.
    Prichard SS. Impact of dyslipidemia in end-stage renal disease. J Am Soc Nephrol 2003;14 (9 Suppl. 4): S315–S320.PubMedCrossRefGoogle Scholar
  27. 27.
    Heimburger O, Stenvinkel P, Berglund L, Tranaeus A, Lindholm B. Increased plasma lipoprotein(a) in continuous ambulatory peritoneal dialysis is related to peritoneal transport of proteins and glucose. Nephron 1996; 72: 135–144.PubMedCrossRefGoogle Scholar
  28. 28.
    Pernod G, Bosson JL, Golshayan D, Barro C, Forneris G, Martina G, et al. Phenotypic and genotypic risk factors for cardiovascular events in an incident dialysis cohort. Kidney Int 2006; 69 (8): 1424–1130.PubMedGoogle Scholar
  29. 29.
    Saltissi D, Morgan C, Rigby RJ, Westhuyzen J. Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis. Am J Kidney Dis 2002; 39 (2): 283–290.PubMedCrossRefGoogle Scholar
  30. 30.
    Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353 (3): 238–248.PubMedCrossRefGoogle Scholar
  31. 31.
    Alvestrand A. Carbohydrate and insulin metabolism in renal failure. Kidney Int 1997; 52 (Suppl. 62): S48–S52.Google Scholar
  32. 32.
    Shinohara K, Shoji T, Emoto M, Takahara H, Koyama H, Ishimura E, et al. Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol 2002; 13: 1894–1900.PubMedCrossRefGoogle Scholar
  33. 33.
    Shen Y, Peake PW, Kelly JJ. Should we quantify insulin resistance in patients with renal disease? Nephrology (Carlton) 2005; 10 (6): 599–605.CrossRefGoogle Scholar
  34. 34.
    Mak RH. Insulin resistance in uremia: effect of dialysis modality. Pediatr Res 1996; 40 (2): 304–308.PubMedCrossRefGoogle Scholar
  35. 35.
    Kobayashi S, Maejima S, Ikeda T, Nagase M. Impact of dialysis therapy on insulin resistance in end-stage renal disease: comparison of haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 2000; 15 (1): 65–70.PubMedCrossRefGoogle Scholar
  36. 36.
    Amici G, Orrasch M, Da Rin G, Bocci C. Hyperinsulinism reduction associated with icodextrin treatment in continuous ambulatory peritoneal dialysis patients. Adv Perit Dial 2001; 17: 80–83.PubMedGoogle Scholar
  37. 37.
    Furuya R, Odamaki M, Kumagai H, Hishida A. Beneficial effects of icodextrin on plasma level of adipocytokines in peritoneal dialysis patients. Nephrol Dial Transplant 2006; 21: 494–498.PubMedCrossRefGoogle Scholar
  38. 38.
    Kalantar-Zadeh K, Kopple JD. Obesity paradox in patients on maintenance dialysis. Contrib Nephrol 2006; 151: 57–69.PubMedCrossRefGoogle Scholar
  39. 39.
    de Mutsert R, Snijder MB, van der Sman-de Beer F, Seidell JC, Boeschoten EW, Krediet RT, et al. The association between body mass index and mortality is similar in the hemodialysis population and the general population at high age and equal duration of follow-up. J Am Soc Nephrol 2007; 18; 967–974.PubMedCrossRefGoogle Scholar
  40. 40.
    Kalantar-Zadeh K, Kuwae N, Wu DY, Shantouf RS, Fouque D, Anker SD, et al. Associations of body fat and its changes over time with quality of life and prospective mortality in hemodialysis patients. Am J Clin Nutr 2006; 83: 202–210.PubMedGoogle Scholar
  41. 41.
    Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant of uremia: oxidative stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62: 1524–1538.PubMedCrossRefGoogle Scholar
  42. 42.
    Noh H, Kim JS, Lee GT, Song JS, Chung SH, Jeon JS, et al. Oxidative stress during peritoneal dialysis: implications in functional and structural changes in the membrane. Kidney Int 2006; 69: 2022–2028.PubMedCrossRefGoogle Scholar
  43. 43.
    Dounousi E, Papavasiliou E, Makedou A, Ioannou K, Katpodis KP, Tselepis A, et al. Oxidative stress is progressively enhanced with advancing stages of CKD. Am J Kidney Dis 2006; 48: 752–760. PubMedCrossRefGoogle Scholar
  44. 44.
    Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000; 356 (9237): 1213–1218.PubMedCrossRefGoogle Scholar
  45. 45.
    Tepel M, van der Giet M, Statz M, Jankowski J, Zidek W. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation 2003; 107 (7): 992–995.PubMedCrossRefGoogle Scholar
  46. 46.
    Mittermayer F, Schaller G, Pleiner J, Vychytil A, Sunder-Plassman G, Hörl WH, et al. Asymmetrical dimethylarginine plasma concentrations are related to basal nitric oxide release but not endothelium-dependent vasodilation of resistance arteries in peritoneal dialysis patients. J Am Soc Nephrol 2005; 16: 1832–1838.PubMedCrossRefGoogle Scholar
  47. 47.
    Suliman M, Qureshi AR, Heimbürger O, Lindholm B, Stenvinkel P. Soluble adhesion molecules in end stage renal disease: a predictor of outcome. Nephrol Dial Transpl 2006; 21: 1603–1610.CrossRefGoogle Scholar
  48. 48.
    Ravani P, Tripepi G, Malberti F, Testa S, Mallamaci F, Zoccali C. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 2005; 16: 2449–2455.PubMedCrossRefGoogle Scholar
  49. 49.
    Zoccali C, Bode-Böger SM, Mallamaci F, Bendetto FA, Tripepi G, Malatino L, et al. Plasma concentrations of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358: 2113–2117.PubMedCrossRefGoogle Scholar
  50. 50.
    Aslam S, Santha T, Leone A, Wilcox C. Effects of amlodipine and valsartan on oxidative stress and plasma methylarginine in end-stage renal disease pateints on hemodialysis. Kidney Int 2006; 70: 2109–2115.PubMedGoogle Scholar
  51. 51.
    Koc M, Richards HB, Bihorac A, Ross EA, Schold JD, Segal MS. Circulating endothelial cells are associated with future vascular events in hemodialysis patients. Kidney Int 2005; 67: 1079–1083.CrossRefGoogle Scholar
  52. 52.
    Steiner S, Schaller G, Puttinger H, Födinger M, Kopp CW, Seideinger D, et al. History of cardiovascular disease is associated with endothelial progenitor cells in peritoneal dialysis patients. Am J Kidney Dis 2005; 46: 520–528.PubMedCrossRefGoogle Scholar
  53. 53.
    Wei M, Esbaei K, Bargman J, Oreopoulos DG. Relationship between serum magnesium, parathyroid hormone, and vascular calcification in patients on dialysis: a literature review. Perit Dial Int 2006; 26 (3): 366–373.PubMedGoogle Scholar
  54. 54.
    Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001; 38 (4): 938–942.PubMedCrossRefGoogle Scholar
  55. 55.
    Wang AY, Wang M, Woo J, Lam CW, Li PK, Lui SF, et al. Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study. J Am Soc Nephrol 2003;14 (1): 159–168.PubMedCrossRefGoogle Scholar
  56. 56.
    Stompor T, Krasniak A, Sulowicz W, Dembinska-Kiec A, Janda K, Wojcik K, et al. Changes in common carotid artery intima-media thickness over 1 year in patients on peritoneal dialysis. Nephrol Dial Transplant 2005; 20 (2): 404–412.PubMedCrossRefGoogle Scholar
  57. 57.
    Wang AY, Woo J, Lam CW, Wang M, Chan IH, Gao P, et al. Associations of serum fetuin-A with malnutrition, inflammation, atherosclerosis and valvular calcification syndrome and outcome in peritoneal dialysis patients. Nephrol Dial Transplant 2005; 20 (8): 1676–1685.PubMedCrossRefGoogle Scholar
  58. 58.
    Chertow GM, Burhe SK, Raggi P. Treat to goal working group, sevelamer alternates the progression of corornary and adinocalcification in hemodialysis patients. Kidney Int 2002; 62: 245–52.PubMedCrossRefGoogle Scholar
  59. 59.
    Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007; 71: 438–441.PubMedCrossRefGoogle Scholar
  60. 60.
    Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto A, Tripepi G, et al. Plasma norpeinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 2002; 105: 1354–1359.PubMedCrossRefGoogle Scholar
  61. 61.
    Tracey KJ. Physiology and immunology of the cholinergic antiinflammatory pathway. J Clin Invest 2007; 117: 289–296.PubMedCrossRefGoogle Scholar
  62. 62.
    Pressman MP, Benz RL, Schleifer CR, Peterson DD. Sleep disordered breathing in ESRD: acute beneficial effects of treatment with nasal continuous positive airway pressure. Kidney Int 1993; 43: 1134–1139.PubMedCrossRefGoogle Scholar
  63. 63.
    Zoccali C, Mallamaci F, Tripepi G. Nocturnal hypoxemia predicts incident cardiovascular complications in dialysis pateints. J Am Soc Nephrol 2002; 13: 729–733.PubMedCrossRefGoogle Scholar
  64. 64.
    Marin JM, Carrizo SJ, Vincente E, Augusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet 2005; 365: 1046–1053.PubMedGoogle Scholar
  65. 65.
    Tang SCW, Lam BL, Ku PP, Leung WS, Chu CM, Ho YW, et al. Alleviation of sleep apnea in patients with chronic renal failure by nocturnal cycler-assisted peritoneal dialysis compared with conventional continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 2006; 17: 2607–2616.PubMedCrossRefGoogle Scholar
  66. 66.
    Suliman M, Heimbürger O, Barany P, Anderstam B, Pecoits-Filho R, Ayala ER, et al. Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy. J Am Soc Nephrol 2003; 14: 1614–1622.PubMedCrossRefGoogle Scholar
  67. 67.
    Schwedler S, Schinzel R, Vaith P, Wanner C. Inflammation and advanced glycation end products in uremia: simple coexistence, potentiation or causal relationship? Kidney Int 2001; 59 (Suppl. 78): S32–S36.CrossRefGoogle Scholar
  68. 68.
    Schwenger V, Morath C, Schonfelder K, Klein W, Weigel K, Deppisch R, et al. An oral load of the early glycation compound lactuloselysine fails to accumulate in the serum of uraemic patients. Nephrol Dial Transplant 2006; 21: 383–388.PubMedCrossRefGoogle Scholar
  69. 69.
    Schwenger V, Morath C, Salava A, Amann K, Seregin Y, Deppisch R, et al. Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced glycation end-products. J Am Soc Nephrol 2006; 17: 199–207.PubMedCrossRefGoogle Scholar
  70. 70.
    Suliman ME, Barany P, Kalantar-Zadeh K, Lindholm B, Stenvinkel P. Homocysteine in uraemia--a puzzling and conflicting story. Nephrol Dial Transplant 2005; 20 (1): 16–21.PubMedCrossRefGoogle Scholar
  71. 71.
    Cook JW, Taylor LM, Orloff SL, Landry GJ, Moneta GL, Porter JM. Homocysteine and arterial disease. Experimental mechanisms. Vascul Pharmacol 2002; 38 (5): 293–300.PubMedCrossRefGoogle Scholar
  72. 72.
    Aucella F, Margaglione, M., Grandone E, Vigilante M, Gatta G, Forcella M, Ktena M, et al. The C667T methylenetetrahydrofolate reductase gene mutation does not influence cardiovascular risk in the dialysis population: results of a multicenter prospective study. Nephrol Dial Transplant 2005; 20: 382–386.PubMedCrossRefGoogle Scholar
  73. 73.
    Wrone EM, Hornberger JM, Zehnder JL, McCann LM, Coplon NS, Fortmann SP. Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol 2004; 15: 420–426.PubMedCrossRefGoogle Scholar
  74. 74.
    Zoungas S, McGrath BP, Branley P, et al. Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial. J Am Coll Cardiol 2006; 47: 1108–1116.PubMedCrossRefGoogle Scholar
  75. 75.
    Righetti M, Tommasi A, Lagona C, La Rosa L, Uccellini M, Sessa A. Effective homocysteine-lowering vitamin B treatment in peritoneal dialysis patients. Perit Dial Int 2004; 24 (4): 373–377.PubMedGoogle Scholar
  76. 76.
    Balakrishnan VS, Guo D, Rao M, Jaberm B.L., Tighiouart H, Freeman RL, et al. Cytokine gene polymorphisms in hemodialysis patients: association with comorbidity, functionality, and serum albumin. Kidney Int 2004; 65: 1449–1460.PubMedCrossRefGoogle Scholar
  77. 77.
    Gillerot G, Goffin E, Michel C, Evenepoel P, Biesen WV, Tintillier M, et al. Genetic and clinical factors influence the baseline permeability of the peritoneal membrane. Kidney Int 2005; 67 (6): 2477–2487.PubMedCrossRefGoogle Scholar
  78. 78.
    Szeto C-C, Chow K-M, Poon P, Szeto CY-K, Wong TY-H, Li P. Genetic polymorphisms of VEGF: Impact on longitudinal change of peritoneal transport and survival of peritoneal dialysis patients. Kidney Int 2004; 65: 1947–1955.PubMedCrossRefGoogle Scholar
  79. 79.
    Wong TY-H, Szeto C-C, Szeto CY-K, Lai K-B, Chow K-M, Li P. Association of ENOS polymorphisms with basal peritoneal membrane function in uremic patients. Am J Kidney Dis 2003; 42: 781–786.PubMedCrossRefGoogle Scholar
  80. 80.
    Sharples EJ, Varagunam M, Sinnott PJ, McCloskey DJ, Raftery MJ, Yaqoob MM. The effect of proinflammatory cytokine gene and angiotensin-converting enzyme polymorphisms on erythropoietin requirements in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 2006; 26 (1): 64–68.PubMedGoogle Scholar
  81. 81.
    Dong C, Yoon W, Goldsmith-Clermont PJ. DNA methylation and atherosclerosis. J Nutr 2002; 132: 2406S–2409S.PubMedGoogle Scholar
  82. 82.
    Hodge DR, Peng B, Cherry JC, Hurt EM, Fox SD, Kelley JA, et al. Interleukin 6 supports the maintenance of p53 tumor suppressor gene promotor methylation. Cancer Res 2005; 65: 4673–4682.PubMedCrossRefGoogle Scholar
  83. 83.
    Stenvinkel P, Karimi M, Johansson S, Axelsson J, Suliman M, Lindholm B, et al. Impact of inflammation on epigenetic DNA methylation – a novel risk factor for cardiovascular disease? J Int Med 2007; 261: 488–499.CrossRefGoogle Scholar
  84. 84.
    Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387–1397.PubMedCrossRefGoogle Scholar
  85. 85.
    Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000; 35 (3): 469–476.PubMedCrossRefGoogle Scholar
  86. 86.
    Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648–658.PubMedCrossRefGoogle Scholar
  87. 87.
    Iseki K, Tozawa M, Yoshi S, Fukiyama K. Serum C-reactive (CRP) and risk of death in chronic dialysis patients. Nephrol Dial Transplant 1999; 14: 1956–1960.PubMedCrossRefGoogle Scholar
  88. 88.
    Noh H, Lee SW, Kang SW, Shin SK, Choi KH, Lee HY, et al. Serum C-reactive protein: a predictor of mortality in continuous ambulatory peritoneal dialysis patients. Nephrol Dial Transplant 1998; 18: 387–394.Google Scholar
  89. 89.
    Ducloux D, Bresson-Vautrin C, Kribs M, Abdelfatah A, Chalopin J-M. C-reactive protein and cardiovascular disease in peritoneal dialysis patients. Kidney Int 2002; 62: 1417–1422.PubMedCrossRefGoogle Scholar
  90. 90.
    Wang A, Woo J, Wai Kei C, Wang M, Man.Sei M, Lui S-F, et al. Is a single time-point C-reactive protein predictive of outcome in peritoneal dialysis patients? J Am Soc Nephrol 2003; 14: 1871–1879.PubMedCrossRefGoogle Scholar
  91. 91.
    Menon V, Greene T, Wang X, Pereira AA, Marcovina SM, Beck GJ, et al. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int 2005; 68: 766–772.PubMedCrossRefGoogle Scholar
  92. 92.
    Stenvinkel P, Wanner C, Metzger T, Heimbürger O, Mallamaci F, Tripepi G, et al. Inflammation and outcome in end-stage renal failure: Does female gender constitute a survival advantage? Kidney Int 2002; 62: 1791–1798.PubMedCrossRefGoogle Scholar
  93. 93.
    Bradbury B, Krishnan M, Critchlow C. Correlation of C-Reactive Protein (CRP) Levels and Markers of Disease Severity in Hemodialysis (HD) Patients. J Am Soc Nephrol 2006; 35: 465A.Google Scholar
  94. 94.
    Herzig KA, Purdie DM, Chang W, Brown AM, Hawley CM, Campbell SB, et al. Is C-reactive protein a useful predictor of outcome in peritoneal dialysis patients? J Am Soc Nephrol 2001; 12: 814–821.PubMedGoogle Scholar
  95. 95.
    Johnson DW, Wiggins KJ, Armstrong A, Campbell SB, Isbel NM, Hawley CM. Elevated white cell count at commencement of peritoneal dialysis predicts overall and cardiac mortality. Kidney Int 2005; 67: 738–743.PubMedCrossRefGoogle Scholar
  96. 96.
    Bologa RM, Levine DM, Parker TS, Cheigh JS, Seur D, Stenzel KH, et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 1998; 32: 107–114.PubMedCrossRefGoogle Scholar
  97. 97.
    Pecoits-Filho R, Barany B, Lindholm B, Heimbürger O, Stenvinkel P. Interleukin-6 and its receptor is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant 2002; 17: 1684–1688.PubMedCrossRefGoogle Scholar
  98. 98.
    Panichi V, Maggiore U, Taccola D, Migliori M, Rizza GM, Consani C, et al. Interleukin-6 is a stronger predictor of total and cardiovascular mortality than C-reactive protein in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 1154–1160.PubMedCrossRefGoogle Scholar
  99. 99.
    Zoccali C, Mallamaci F, Tripepi G, Cutrupi S, Parlongo S, Malatino LS, et al. Fibrinogen, mortality and incident cardiovascular complications in end-stage renal failure. J Intern Med 2003; 254: 132–139.PubMedCrossRefGoogle Scholar
  100. 100.
    Foley RN, Guo H, Snyder JJ, Gilbertson DT, Collins AJ. Septicemia in the United States dialysis population 1991–1999. J Am Soc Nephrol 2004; 15: 1038–1045.PubMedCrossRefGoogle Scholar
  101. 101.
    Shlipak MG, Fried LF, Cushman M, Manolio TA, Peterson D, Stehman-Breen C, et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA 2005; 293: 1737–1745.PubMedCrossRefGoogle Scholar
  102. 102.
    Landray MJ, Wheeler DC, Lip GY, Newman DJ, Blann AD, McGlynn FJ, et al. Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. Am J Kidney Dis 2004; 43: 244–253.PubMedCrossRefGoogle Scholar
  103. 103.
    Oberg BP, Mcmenamin E, Lucas FL, Mcmonagle E, Morrow J, Ikizler TA, et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 2004; 65: 1009–1016.PubMedCrossRefGoogle Scholar
  104. 104.
    Muntner P, Hamm L, Kusek JW, Chen J, Whelton PK, He J. The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease. Ann Intern Med 2004; 140: 9–17.PubMedGoogle Scholar
  105. 105.
    Shlipak MG, Fried LF, Crump C, Bleyer AJ, Manolio TA, Tracy RP, et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 2003; 107: 87–92.PubMedCrossRefGoogle Scholar
  106. 106.
    van Tellingen A, Grooteman MPC, Schoorl M, Bartels PCM, Schoorl M, van der Ploeg T, et al. Intercurrent clinical events are predictive of plasma C-reactive protein levels in hemodialysis patients. Kidney Int 2002; 62: 632–638.PubMedCrossRefGoogle Scholar
  107. 107.
    Stenvinkel P, Heimbürger O, Jogestrand T. Elevated interleukin-6 predicts progressive carotid atherosclerosis in dialysis patients: association to chlamydia pneumoniae seropositivity. Am J Kidney Dis.2002; 39: 274–282.PubMedCrossRefGoogle Scholar
  108. 108.
    Haubitz M, Brunkhorst R. C-reactive protein and chronic Chlamydia pneumonia infection – long term predictors of cardiovascular disease survival in patients on peritoneal dialysis. Nephrol Dial Transplant 2001; 16: 809–815.PubMedCrossRefGoogle Scholar
  109. 109.
    Sezer S, Ibis A, Ozdemir BH, Ozdemir FN, Kulah E, Boyacioglu S, et al. Association of Helicobacter pylori infection with nutritional status in hemodialysis patients. Transpl Proc 2004; 36: 47–49.CrossRefGoogle Scholar
  110. 110.
    Craig RG, Spittle MA, Levin NM. Importance of periodontal disease in the kidney patient. Blood Purif 2002; 20: 113–119.PubMedCrossRefGoogle Scholar
  111. 111.
    Axelsson J, Qureshi AR, Suliman ME, Honda H, Pecoits-Filho R, Heimbürger O, et al. Truncal fat mass as a contributor to inflammation in end-stage renal disease. Am J Clin Nutr 2004; 80: 1222–1229.PubMedGoogle Scholar
  112. 112.
    Pecoits-Filho R, Heimbürger O, Bárány P, Suliman M, Fehrman-Ekholm I, Lindholm B, et al. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis 2003; 41: 1212–1218.PubMedCrossRefGoogle Scholar
  113. 113.
    Feldman AM, Combes A, Wagner D, Kadakomi T, Kubota T, Li YY, et al. The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol 2000; 35: 537–544.PubMedCrossRefGoogle Scholar
  114. 114.
    Niebauer J, Volk H-D, Kemp M, Dominguez M, Schumann RR, Rauchhaus M, et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 1999; 353: 1838–1842.PubMedCrossRefGoogle Scholar
  115. 115.
    Wang AY, Wang M, Woo J, Lam CW, Lui SF, Li PK, et al. Inflammation, residual kidney function, and cardiac hypertrophy are interrelated and combine adversely to enhance mortality and cardiovascular death risk of peritoneal dialysis patients. J Am Soc Nephrol 2004; 15: 2186–2194.PubMedCrossRefGoogle Scholar
  116. 116.
    Lopez-Gomez JM, Perez-Flores I, Jofre R, Carretero D, Rodriguez-Beniter P, Villaverde M, et al. Presence of a failed kidney transplant in patients who are on hemodialysis is associated with chronic inflammatory state and erythropoietin resistance. J Am Soc Nephrol 2004; 15: 2494–2501.PubMedCrossRefGoogle Scholar
  117. 117.
    Ayus JC, Sheikh-Hamad D. Silent infection in clotted hemodialysis access grafts. J Am Soc Nephrol 1998; 9: 1314–1321.PubMedGoogle Scholar
  118. 118.
    Caglar K, Peng Y, Pupim LB, Flakoll PJ, Levenhagen D, Hakim RM, et al. Inflammatory signals associated with hemodialysis. Kidney Int 2002; 62: 1408–1416.PubMedCrossRefGoogle Scholar
  119. 119.
    Allon M, Depner TA, Radeva M, Bailey J, Beddhu S, Butterly D, et al. Impact of dialysis dose and membrane on infection-related hospitalization and death: results of the HEMO study. J Am Soc Nephrol 2003; 14: 1863–1870.PubMedCrossRefGoogle Scholar
  120. 120.
    Friedrich B, Alexander D, Janessa A, Häring H-H, Lang F, Risler T. Acute effects of hemodialysis on cytokine transcription profiles: evidence for C-reactive protein-dependency on mediator induction. Kidney Int 2006; 70: 2124–2130.PubMedGoogle Scholar
  121. 121.
    Carrero JJ, Axelsson J, Avesani CM, Heimbürger O, Lindholm B, Stenvinkel P. Being an inflamed peritoneal dialysis patient – a Dantés journey. Contrib Nephrol 2006; 150: 144–151.PubMedCrossRefGoogle Scholar
  122. 122.
    Krishnan M, Tam P, Wu G, Breborowicz A, Oreopoulos DG. Glucose degradation products (GDP’s) and peritoneal changes in patients on chronic peritoneal dialysis: will new dialysis solutions prevent these changes? Int Urol Nephrol 2005; 37 (2): 409–418.PubMedCrossRefGoogle Scholar
  123. 123.
    Reaich D, Graham KA, Channon SM, Hetherington C, Scrimgeour CM, Wilkinson R, et al. Insulin-mediated changes in PD and glucose uptake after correction of acidosis in humans with CRF. Am J Physiol 1995; 268 (1 Pt 1): E121–E126.PubMedGoogle Scholar
  124. 124.
    Dandona P, Mohanty P, Chaudhuri A, Garg R, Aljada A. Insulin infusion in acute illness. J Clin Invest 2005; 115: 2069–2072.PubMedCrossRefGoogle Scholar
  125. 125.
    Enriquez J, Klinger J, Arturo JA, Delgado M, Tobar C, Mosquera M. Peritonitis in continuous ambulatory peritoneal dialysis: cytokines in peritoneal fluid and blood. Adv Perit Dial 2002; 18: 177–183.PubMedGoogle Scholar
  126. 126.
    Enia G, Mallamaci F, Benedetto FA, Panuccio V, Parlongo S, Cutrupi S, et al. Long-term CAPD patients are volume expanded and display more severe left ventricular hypertrophy than haemodialysis patients. Nephrol Dial Transplant 2001; 16 (7): 1459–1464.PubMedCrossRefGoogle Scholar
  127. 127.
    Sezer S, Tutal E, Arat Z, Akcay A, Celik H, Ozdemir FN, et al. Peritoneal transport status influence on atherosclerosis/inflammation in CAPD patients. J Ren Nutr 2005; 15 (4): 427–434.PubMedCrossRefGoogle Scholar
  128. 128.
    Pankow JS, Folsom AR, Cushman M, Borecki IB, Hopkins PN, Eckfeldt JH, et al. Familial and genetic determinants of systemic markers of inflammation: the NHLBI family heart study. Atherosclerosis 2001; 154: 681–689.PubMedCrossRefGoogle Scholar
  129. 129.
    Tsirpanlis G, Bagos P, Ioannou D, Bleta A, Marinou I, Lagouranis A, et al. The variability and accurate assessment of microinflammation in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 150–157.PubMedCrossRefGoogle Scholar
  130. 130.
    Witasp A, Nordfors L, Lindholm B, Stenvinkel P. Use of single nucleotide polymorphisms in the search for genetic modifiers of the uremic phenotype. J Renal Nutr 2007; 17: 17–22.CrossRefGoogle Scholar
  131. 131.
    Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340: 115–126.PubMedCrossRefGoogle Scholar
  132. 132.
    Yeh ETH. CRP as a mediator of disease. Circulation 2004; 109 (suppl. II): II-11–II-14.CrossRefGoogle Scholar
  133. 133.
    Stenvinkel P, Ketteler M, Johnson RJ, Lindholm B, Pecoits-Filho R, Riella M, et al. Interleukin-10, IL-6 and TNF-a: important factors in the altered cytokine network of end-stage renal disease – the good, the bad and the ugly. Kidney Int 2005; 67: 1216–1233.PubMedCrossRefGoogle Scholar
  134. 134.
    Pasceri V, Cheng JS, Willerson JT, Yeh ET, Chang JW. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001; 103: 2531–2534.PubMedGoogle Scholar
  135. 135.
    Gill R, Kemp JA, Sabin C, Pepys MB. Human C-reactive protein increases cerebral infarct size after middle cerebral artery occlusion in adult rats. J Cereb Blood Flow Metab 2004; 24: 1214–1218.PubMedCrossRefGoogle Scholar
  136. 136.
    Verma S, Kuliszewski MA, Li SH, Szmitko PE, Zucco L, Wang CH, et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 2004; 109: 2058–2067.PubMedCrossRefGoogle Scholar
  137. 137.
    Wang CH, Li SH, Weisel RD, Fedak PW, Dumont AS, Szmitko P, et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 2003; 107: 1783–1790.PubMedCrossRefGoogle Scholar
  138. 138.
    Pepys MB, Hirschfield GM, Tennent GA, Gallimore JR, Kahan MC, Belloti V, et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 2006; 440: 1217–1221.PubMedCrossRefGoogle Scholar
  139. 139.
    Zoccali C, Testa A, Spoto B, Tripepi G, Mallamaci F. Mendelian randomization: a new approach to studying epidemiology in ESRD. Am J Kidney Dis 2006; 47: 332–341.PubMedCrossRefGoogle Scholar
  140. 140.
    Casas JP, Shah T, Cooper J, Haw E, McMahon AD, Gaffney D, et al. Insight into the nature of the CRP-coronary event association using Mendelian randomization. Int J Epidemiol 2006; 35: 922–931.PubMedCrossRefGoogle Scholar
  141. 141.
    Timpson NJ, Lawlor DA, Harbord RM, Gaunt TR, Day INM, Palmer LJ, et al. C-reactive protein and its role in metabolic syndrome: Mendelian randomization study. Lancet 2005; 366: 1954–1959.PubMedCrossRefGoogle Scholar
  142. 142.
    Davey Smith G, Lawlor DA, Harbord R, Timpson N, Rumley A, Lowe GD, et al. Association of C-reactive protein with blood pressure and hypertension: life course confounding and Mendelian randomization tests of causality. Arterioscler Thromb Vasc Biol 2005; 25: 1051–1056.PubMedCrossRefGoogle Scholar
  143. 143.
    Zhang L, Kao L, Berthier-Schaad Y, Plantinga L, Fink N, Smith MW, et al. C-reactive protein haplotype predicts serum C-reactive protein levels but not cardiovascular disease risk in a dialysis cohort. Am J Kidney Dis 2007; 49: 118–126.PubMedCrossRefGoogle Scholar
  144. 144.
    Liu Y, Berthier-Schaad Y, Fallin MD, Fink NE, Tracy RP, Klag MJ, et al. Interleukin 6 haplotypes, inflammation, and risk of cardiovascular disease in a multiethnic dialysis cohort. J Am Soc Nephrol 2006; 17: 863–870.PubMedCrossRefGoogle Scholar
  145. 145.
    Stenvinkel P. Inflammation in end-stage renal failure: could it be treated? Nephrol Dial Transpl 2002; 17 (suppl. 8): 33–38.CrossRefGoogle Scholar
  146. 146.
    Sjoland JA, Pedersen RS, Jespersen J, Gram J. Intraperitoneal heparin ameliorates inflammatory response in PD patients. Nephron Clin Pract 2005; 100: c105–c110.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Division of Renal Medicine K56Karolinska University Hospital at HuddingeSweden
  2. 2.Department of Internal Medicine, Division of Nephrology, Im Neuenheimer Feld 162University of HeidelbergGermany

Personalised recommendations